Noninvasive assessment of liver damage in chronic hepatitis B

doi:10.4254/wjh.v5.i8.439

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5414)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

414

HTML

2941

Figures (1-1)

260

Tables (1-4)

270

Sum=3885

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

895

Download

634

Sum=1529

Aug 27, 2013 (publication date) through Feb 6, 2025

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Hepatol. Aug 27, 2013; 5(8): 439-444
Published online Aug 27, 2013. doi: 10.4254/wjh.v5.i8.439

Table 1 Comparison of clinical and laboratory parameters between control and hepatitis B patients groups

Variable	Control (n = 43)	Hepatitis B patients (n = 89)	P value
Gender (female/male)	31 (72.1)/12 (27.9)	39 (43.8)/50 (56.2)	0.004
Age (yr)	35.4 ± 12.64	41.5 ±1 3.02	0.012
Platelet count (10³μL)	272.0 (242-342)	179.0 (147-231)	< 0.001
Total bilirubin (mg/dL)	0.6 (0.4-0.8)	0.8 (0.6-1)	0.009
AST (IU/L)	17.0 (14-20)	45.0 (30-68)	< 0.001
ALT (IU/L)	16.0 (11-19)	56.0 (36-111)	< 0.001
AP (IU/L)	69.0 (53-79)	72.0 (61-90)	0.086
GGT (IU/L)	17.0 (14-27)	29.0 (21-50)	< 0.001
Neutrophil count	4.3 (3.4-4.9)	3.4 (2.9-4.7)	0.004
Lymphocyte count	2.1 (1.6-2.4)	2.0 (1.6-2.4)	0.355
N/L	2.1 (1.5-2.8)	1.9 (1.4-2.3)	0.123
APRI score	0.1 (0.1-0.1)	0.6 (0.3-1.1)	< 0.001

Values are expressed as n (%), mean ± SD or median (25^th-75^th percentiles). AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AP: Alkaline phosphatase; GGT: Gamma glutamyl transferase; N/L: Neutrophil-lymphocyte ratio; APRI: Aspartate aminotransferase/platelet ratio index.

Table 2 Between group comparisons and logistic regression results in chronic hepatitis B patients according to fibrosis stage

Variable	Between group comparisons			Logistic regression analysis
Variable	No/mild fibrosis (n = 34)	Significant fibrosis (n = 55)	P value	Univariate OR (95%CI)	Multivariate OR (95%CI)
Gender (female/male)	16 (47.1)/18 (52.9)	23 (41.8) /32 (58.2)	0.792	1.2 (0.5-2.9)	-
Age (yr)	40.2 ± 11.7	42.2 ± 13.7	0.473	1.01 (0.9-1.05)	-
HGB	14.4 ± 2.08	14.6 ± 1.8	0.735	1.04 (0.8-1.3)	-
Platelet Count (10³μL)	203 (176-232)	171 (115-227)	0.010	0.9 (0.9-1)	0.9 (0.9-1)
INR	1.07 ± 0.1	1.13 ± 0.1	0.045	34.5 (1.01-1183.1)	-
Albumine	4.06 ± 0.3	4.01 ± 0.3	0.466	0.6 (0.1-2.3)	-
Total bilirubin (mg/dL)	0.7 (0.5-0.9)	0.8 (0.6-1.1)	0.110	3.05 (0.8-10.8)	-
AST (IU/L)	41.5 (27-73)	47 (32-68)	0.447	1 (0.9-1.01)	-
ALT (IU/L)	57 (33-132)	54 (36-106)	0.866	1 (0.9-1.01)	-
AP (IU/L)	71.5 (62-89)	73 (61-100)	0.630	1.01 (0.9-1.02)	-
GGT (IU/L)	27 (19-48)	36 (23-52)	0.119	1.01 (0.9-1.03)	-
HBV DNA	346 (1.9-1000)	75.7 (1.8-1000)	0.838	1 (0.9-1.01)	-
HBeAg (negative/positive)	30 (88.2)/4 (11.8)	45 (81.8)/10 (18.2)	0.611	1.6 (0.4-5.8)	-
Neutrophil count	3.2 (2.7-4.8)	3.5 (3.04-4.7)	0.569	0.9 (0.6-1.2)	-
Lymphocyte count	1.9 (1.4-2.3)	2 (1.6-2.4)	0.630	0.9 (0.5-1.7)	-
N/L	1.9 (1.3-2.5)	1.8 (1.5-2.2)	0.859	0.8 (0.5-1.3)	-
APRI score	0.5 (0.3-0.9)	0.7 (0.3-1.4)	0.060	1.2 (0.7-2.1)	-

Values are expressed as n (%), mean ± SD or median(25^th-75^th percentiles). HGB: Hemoglobin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AP: Alkaline phosphatase; GGT: Gamma glutamyl transferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; N/L: Neutrophil-lymphocyte ratio; APRI: Aspartate aminotransferase/platelet ratio index.

Table 3 Between group comparisons and logistic regression results in chronic hepatitis B patients according to cirrhosis

Variable	Between group comparisons			Logistic regression analysis
Variable	Non-cirrhotic (n = 76)	Cirrhotic (n = 13)	P value	Univariate OR (95%CI)	Multivariate OR (95%CI)
Gender (female/male)	33 (43.4)/43 (56.6)	6 (46.2)/7 (53.8)	0.999	1.1 (0.3-3.6)	-
Age (yr)	40.2 ± 12.3	49.08 ± 15.04	0.022	1.06 (1.01-1.1)	1.06 (1-1.11)
HGB	14.5 ± 2.03	14.6 ± 1.37	0.891	1.0 (0.7-1.39)	-
Platelet count (10³μL)	190.5 (152-233.5)	152 (117-175)	0.051	0.9 (0.9-1)	-
INR	1.1 ± 0.1	1.1 ± 0.09	0.250	6.3 (0.09-478.1)	-
Albumine	4.04 ± 0.3	3.9 ± 0.4	0.210	0.2 (0.04-2.01)	-
Total bilirubin (mg/dL)	0.8 (0.6-1)	1 (0.6-1.3)	0.389	2.09 (0.5-8.7)	-
AST (IU/L)	41.5 (28-65)	66 (40-79)	0.078	1 (0.9-1.01)	-
ALT (IU/L)	54 (33-124)	69 (51-97)	0.419	1 (0.9-1.01)	-
AP (IU/L)	72 (61-89.5)	82 (62-116)	0.225	1.02 (1-1.03)	1.02 (1-1.04)
GGT (IU/L)	28 (20-50.5)	47 (26-50)	0.189	1.01 (1-1.02)	-
HBV DNA	269.5 (2-1000)	10.1 (0.4-1000)	0.339	1 (0.9-1.01)	-
HbeAg (negative/positive)	65 (85.5)/11 (14.5)	10 (76.9)/3 (23.1)	0.423	1.7 (0.4-7.4)	-
Neutrophil count	3.4 (2.8-4.7)	3.8 (3.04-4.1)	0.468	1.05 (0.7-1.5)	-
Lymphocyte count	2 (1.6-2.4)	2 (1.5-2.2)	0.493	0.6 (0.2-1.5)	-
N/L	1.8 (1.3-2.2)	2.04 (1.6-2.8)	0.160	1.3 (0.8-2.07)	-
APRI score	0.5 (0.3-1.08)	1.1 (0.7-1.7)	0.047	1.2 (0.8-2.05)	-

Table 4 Statistical diagnostic measures and Kappa test results of neutrophil-lymphocyte and aspartate aminotransferase/platelet ratio score in the detection of significant fibrosis and cirrhosis

Variable	Diagnostic measures					Kappa test
Variable	SEN (95%CI)	SPE (95%CI)	PPR (95%CI)	NPR (95%CI)	AR (95%CI)	κ	P value
Significant fibrosis
N/L ( ≤ 2.18)	0.73 (0.59-0.84)	0.41 (0.25-0.59)	0.67 (0.53-0.78)	0.48 (0.29-0.67)	0.61 (0.50-0.71)	0.143	0.174
APRI (> 0.56)	0.65 (0.51-0.78)	0.56 (0.38-0.73)	0.71 (0.56-0.83)	0.50 (0.33-0.67)	0.62 (0.51-0.72)	0.209	0.048
Cirrhosis
N/L (> 2.58)	0.38 (0.14-0.68)	0.87 (0.77-0.64)	0.33 (0.12-0.62)	0.89 (0.80-0.95)	0.80 (0.70-0.88)	0.238	0.024
APRI (> 1.01)	0.62 (0.36-0.86)	0.74 (0.62-0.83)	0.29 (0.13-0.49)	0.92 (0.82-0.97)	0.72 (0.61-0.81)	0.238	0.011

SEN: Sensitivity; SPE: Specifity; PPR: Positive predictive rate; NPR: Negative predictive rate; AR: Accuracy rate; APRI: Aspartate aminotransferase/platelet ratio index; N/L: Neutrophil-lymphocyte ratio.

Citation: Celikbilek M, Dogan S, Gursoy S, Zararsız G, Yurci A, Ozbakır O, Guven K, Yucesoy M. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol 2013; 5(8): 439-444
URL: https://www.wjgnet.com/1948-5182/full/v5/i8/439.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i8.439